Q2 FY2026 EarningsQ2 FY26 beat consensus across top and bottom-line metrics: total revenue of $214M vs. $183.3M expected, and GAAP EPS of -$0.90 vs. -$1.22 expected. Crysvita performed strongly with $156M in combined sales and royalties, while Evkeeza grew 50% YoY in ex-U.S. markets. Management confirmed expectations for 2027 profitability, supported by a strategic 10% workforce reduction and lower R&D spend as Phase 3 programs conclude.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Ultragenyx Pharma(RARE) the Revenue is 214 M (+28.53%), Beat estimate;the EBIT is -75 M (+30.48%), Beat estimate;the EPS is -0.9 (+23.08%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.21B28.53%
0.18B10.09%
+0.03B18.44%
EBITExceed expectations
-0.07B30.48%
-0.11B3.62%
+0.04B34.10%
EPSExceed expectations
-0.923.08%
-1.24336.27%
+0.343329.35%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf